AGE Reader

Key publications

The AGE Reader has been validated in over 300 peer-reviewed publications. Please find below a selection of key publications for the different indications of the AGE Reader. 

Kidney disease:

• Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Sep 1. Epub

• The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study. Shardlow A, McIntyre NJ, Kolhe NV, et al. PLoS Med. 2020;17(7):e1003163. doi:10.1371/journal.pmed.1003163

• Skin autofluorescence and malnutrition as predictors of mortality in persons receiving dialysis: a prospective cohort study. Viramontes Hörner D, Selby NM, Taal MW. J Hum Nutr Diet. 2020;33(6):852-861. doi:10.1111/jhn.12764

• Skin autofluorescence associates with vascular calcification in chronic kidney disease. Arterioscler Thromb Vasc Biol.Wang AYM, Wong CK, Yau YY, Wong S, Chan IHS, Lam CWK. 2014;34(8):1784-1790. doi:10.1161/ATVBAHA.114.303378

Diabetes:

• Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes. Boersma HE, van Waateringe RP, van der Klauw MM, et al. BMC Endocr Disord. 2021;21(1):14. doi:10.1186/s12902-020-00676-4

• Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in Type 2 diabetes mellitus. Yozgatli K, Lefrandt JD, Noordzij MJ, et al. Diabet Med. Published online April 23, 2018. doi:10.1111/dme.13651

• Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Lutgers HL, Gerrits EG, Graaff R, et al. Diabetologia. 2009;52(5):789-797. doi:10.1007/s00125-009-1308-9

• Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Meerwaldt R, Lutgers HL, Links TP, et al. Diabetes Care. 2007;30(1):107-112. doi:10.2337/dc06-1391

Cardiovascular disease:

• Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. Cavero-Redondo I, Soriano-Cano A, Álvarez-Bueno C, et al. J Am Heart Assoc. 2018;7(18):e009833. doi:10.1161/JAHA.118.009833
• Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease. de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.

Surgery patients:

• It’s all in our skin-Skin autofluorescence-A promising outcome predictor in cardiac surgery: A single centre cohort study. Hofmann B, Gerull KA, Bloch K, et al. PLoS One. 2020;15(6):e0234847. doi:10.1371/journal.pone.0234847

General population:

• Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study. Banafsheh Arshi, Jinluan Chen, M. Arfan Ikram, M. Carola Zillikens & Maryam Kavousi, Diabetologia 2022
• Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. van Waateringe RP, Fokkens BT, Slagter SN, et al. Diabetologia. 2019;62(2):269-280. doi:10.1007/s00125-018-4769-x